Podcasts about omnia education

CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/key-patient-counseling-issues-surrounding-fnait-and-its-risk-in-subsequent-pregnancies/32283/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/current-management-strategies-for-fnait/32278/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/fetalneonatal-alloimmune-thrombocytopenia-fnait-the-platelet-equivalent-of-rh-disease/32275/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/classificationsuspecting-a-diagnosis-of-fnaitnait/32276/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/current-diagnostic-signs-symptoms-and-lab-tests-for-fnait/32277/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-alloimmune-disorders-of-pregnancy/32274/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-the-next-pregnancy-in-patients-with-an-fnait-affected-first-child/32279/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/screening-for-fnait-anticipating-hpa-1a-incompatibility/32280/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/neonatal-fcrn-inhibition-a-new-pathway-for-addressing-the-alloimmune-disorders-of-pregnancy/32281/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/nipocalimab-an-fcrn-inhibitor-and-its-role-in-treating-hdfn/32282/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

CME credits: 0.50 Valid until: 09-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/case-in-point-the-use-of-gnrh-antagonists-pre-andor-post-surgery-and-the-potential-consequences-of-repeat-surgery/24400/ While both medical therapy and surgery often play a role in a woman's journey with endometriosis, it is less clear how to best sequence these approaches to optimize a patient's outcomes. Under what circumstances should you consider using a GnRH antagonist either before or after conservative surgery? Join Drs. Lee Shulman, Ayman Al-Hendy, and James Simon as they provide their collective thoughts on how best to sequence a GnRH antagonist with conservative surgery when managing endometriosis.=

CME credits: 0.50 Valid until: 09-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/pain-points-weighing-the-benefits-and-drawbacks-of-the-gnrh-antagonists-throughout-the-endometriosis-treatment-journey/24399/ GnRH antagonists have emerged as a viable first-line (or subsequent-line) medical therapy for the management of endometriosis. They have proven to be effective and safe, and their use avoids the flare response observed with GnRH agonists. Join Drs. Lee Shulman, Ayman Al-Hendy, and Sawsan As-Sanie as they discuss the estrogen threshold hypothesis from the perspective of GnRH antagonists and delve into clinical data supporting the use of GnRH antagonists in the medical management of endometriosis.=

CME credits: 0.25 Valid until: 09-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-centric-tools-to-support-shared-decision-making-diagnosing-and-assessing-endometriosis/24398/ The use of validated patient questionnaires, notably the SF-36 and EHP-30 scales, can greatly hasten the suspicion for an endometriosis diagnosis. Coupled with shared decision-making, or SDM, this patient-centered process can help ensure therapeutic adherence. Join Drs. Lee Shulman, Melissa Simon, and Linda Bradley as they discuss how to utilize the SF-36 and EHP-30 questionnaires in clinical practice and explore strategies to facilitate patient-healthcare provider discussions to improve overall short- and long-term patient outcomes.=

CME credits: 0.50 Valid until: 09-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/creating-a-practice-environment-that-enhances-healthcare-equality-for-all-patients/24397/ Both provider- and patient-related healthcare disparities exist in the diagnosis and management of endometriosis. Many disparities derive from incorrect historical biases, while others are associated with social determinants of health, or SDOH. Join Drs. Lee Shulman, Linda Bradley, and Melissa Simon as they address these issues to help facilitate a patient-centered practice environment for all patients.=

CME credits: 0.25 Valid until: 08-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/innovations-in-the-management-of-hemolytic-disease-of-the-fetus-and-newborn-the-role-of-the-neonatal-fc-receptor-fcrn-pathway/16045/ Hemolytic disease of the fetus and newborn (HDFN) is an alloimmune disorder between the mother and fetus, one with significant risk for dire health consequences for both. Fortunately, a better understanding of the neonatal Fc receptor (FcRn) pathway along with the emergence of an inhibitor of this pathway has brought with it an opportunity to greatly reduce the potential harm associated with HDFN. Join us as Drs. Kenneth Moise and Kara Markham discuss the pathophysiology of HDFN and present key clinical data that may change the landscape of medical intervention for HDFN.=

CME credits: 0.25 Valid until: 29-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/consensus-recommendations-for-use-of-p16ki67-dual-staining-cytology-in-the-management-of-individuals-testing-positive-for-hpv/14675/ More effective triage tests are essential to improving cervical cancer risk-stratification and thus reducing the potential for unnecessary colposcopies. Enduring consensus cervical cancer screening recommendations, published in 2024, describe specific-use algorithms for p16/Ki-67 dual-staining cytology as an effective triage test, and also offer insight on how this test can best fit into clinical practice. Join Drs. Warner Huh and Kimberly Levinson as they first establish the rationale for using p16/Ki-67 dual-staining cytology and then break down the most salient algorithms for its use as offered in the recent recommendations.=

CME credits: 0.25 Valid until: 13-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/migraine-clinical-approaches-and-a-patients-perspective/16281/ Half of the women in the US with migraine are never diagnosed. Of those who are, the journey to effective treatment may last a decade or longer. But newer and more effective targeted treatments are beginning to make a difference. Join Drs. Jessica Ailani and Dawn Buse as they discuss a novel approach to managing migraine and interview a patient whose migraine journey is unfortunately one traversed by many women.=

CME credits: 0.25 Valid until: 13-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-centric-approaches-to-managing-migraines-in-the-female-patient/16281/ Half of the women in the US with migraine are never diagnosed. Of those who are, the journey to effective treatment may last a decade or longer. But newer and more effective targeted treatments are beginning to make a difference. Join Drs. Jessica Ailani and Dawn Buse as they discuss a novel approach to managing migraine and interview a patient whose migraine journey is unfortunately one traversed by many women.=

CME credits: 0.75 Valid until: 09-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-centric-management-of-menopausal-symptoms-improving-outcomes-with-individualized-therapy/16532/ Understanding the physiologic basis for the vasomotor symptoms of perimenopause/menopause has led to an improved ability to match a therapeutic approach to each individual patient. New and improved agents are helping to facilitate this dynamic. Join Anita Nelson, MD, and Barbara Dehn, NP, as they provide insights into making the right treatment decision for each patient—one that includes ensuring patient preferences are considered.=

CME credits: 0.75 Valid until: 05-12-2024 Claim your CME credit at https://reachmd.com/programs/cme/migraine-and-womens-health-migraine-and-the-whole-female-patient/15904/ Upwards of 47 million people in the U.S. suffer from migraines, often accompanied by widespread personal, professional, and social disabilities. Though a similar prevalence is initially observed between men and women, by mid-adulthood the prevalence of migraine is 3-fold greater in women than men. Newer agents, both injectable and oral and focused on modulating the calcitonin gene-related peptide pathway, have emerged and have proven highly effective in managing both acute and chronic migraine. Join Drs. Jessica Ailani and Dawn Buse as they provide an overview of the changing landscape of migraine therapy, especially as it impacts women across different life-stages.=

CME credits: 0.50 Valid until: 05-12-2024 Claim your CME credit at https://reachmd.com/programs/cme/postpartum-depression-a-significant-burden-and-a-novel-approach-to-treatment/15685/ The recent development and approval of two neuroactive steroids is likely to change the treatment paradigm for moderate to severe postpartum depression (PPD). These agents have a quick onset and function as GABAA positive allosteric modulators. Join Drs. Shulman and Deligiannidis as they address the burdens and impacts of PPD on mothers, babies, and partners, and deep dive into the pathophysiologic role and clinical findings associated with the use of neuroactive steroids in the management of PPD. =

CME credits: 0.25 Valid until: 12-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/case-of-the-patient-in-midlife-weighing-potential-changes-in-asccp-guidelines/14674/ Effective triage tests are needed to lessen diagnostic uncertainty when assessing cervical cancer risk and selecting which patients will move on to colposcopy. An FDA-approved dual-staining cytology test is available that can help in decision-making for a wide range of patients. Join Drs. Warner Huh and Sarah Dilley as they address current 2019 ASCCP guidelines and anticipate potential updates to ASCCP's guidance in 2023.=

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Roberto Romero, MD, DMedSci Renowned international expert Dr. Roberto Romero joins Dr. Lee Shulman to walk us through maternal anti-fetal rejection. Find out about its pathophysiology, mechanisms of disease, approach to diagnosis, and potential treatment so that you can broaden your understanding and improve the care you provide.

CME credits: 1.00 Valid until: 01-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/in-any-case-the-importance-of-iron-repletion/15137/ This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.

CME credits: 1.00 Valid until: 01-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/enhancing-adherence-with-oral-iron-therapy/15136/ This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.

CME credits: 0.25 Valid until: 01-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/why-are-the-fetus-and-placenta-not-rejected-by-the-mother-new-insights-into-maternal-anti-fetal-rejection/13912/ Renowned international expert Dr. Roberto Romero joins Dr. Lee Shulman to walk us through maternal anti-fetal rejection. Find out about its pathophysiology, mechanisms of disease, approach to diagnosis, and potential treatment so that you can broaden your understanding and improve the care you provide. =

CME credits: 1.00 Valid until: 01-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/how-a-womans-iron-status-today-can-impact-a-babys-health-tomorrow-and-through-the-years/15131/ This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.

CME credits: 1.00 Valid until: 01-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/iron-supplementation-formulations-for-females-with-idida-monitoring-response/15135/ This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.

CME credits: 1.00 Valid until: 01-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/contributors-to-iron-status-serum-ferritin-tsat-and-hemoglobin/15128/ This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.

CME credits: 1.00 Valid until: 01-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/pathogenesis-of-id-and-ida-in-reproductive-aged-women-focus-on-heavy-menstrual-bleeding/15129/ This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.

CME credits: 1.00 Valid until: 01-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/assessing-and-addressing-idida-the-need-for-guidance/15130/ This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.

CME credits: 1.00 Valid until: 01-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/the-impact-and-importance-of-iron-status/15127/ This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.

CME credits: 1.00 Valid until: 01-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/all-oral-iron-therapies-are-not-created-equal/15132/ This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.

CME credits: 1.00 Valid until: 01-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/id-and-ida-in-postmenopausal-women/15133/ This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.

CME credits: 1.00 Valid until: 01-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/strategies-to-effectively-manage-id-and-ida-throughout-the-life-span/15134/ This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.

CME credits: 0.25 Valid until: 07-03-2024 Claim your CME credit at https://reachmd.com/programs/cme/cervical-cancer-screening-the-case-of-the-young-patient/14673/ Explore the case of a young patient to see the ACS and ASCCP cervical cancer screening guidelines in action. Who needs to be screened, how is it best to screen, and what's the best test? Leading experts, Drs. Leigh Cantrell and Warner Huh, review the benefits of primary screening as they explore shifts in current guidelines. Find out how you can improve outcomes for patients, not only through appropriate primary HPV testing in lieu of cytology as the screening modality, but also by reinforcing how a “negative” HPV test actually sends a powerful “positive” message. As a bonus, you might just change a young patient's life.=

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Alexandra Benachi, MD, PhD Guest: Julien Zuber, MD, PhD Program Chairman:Roberto Romero, MD, DMedSciChief, Perinatology Research BranchDivision of Maternal-Fetal Medicine and ObstetricsDivision of Intramural ResearchNICHD/NIH/DHHSEditor-in-Chief for ObstetricsThe American Journal of Obstetrics and Gynecology There exists a long-standing controversy about drawing parallels between transplant and pregnancy immunology. Listen in as Drs. Alexandra Benachi, Julien Zuber, and Lee Shulman discuss why these considerations are so important for you and your colleagues, patients, and their families to understand. Discover how links between kidney transplantation and maternal anti-fetal rejection may impact your practice and spark new pathways in medicine.

CME credits: 0.25 Valid until: 28-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/parallels-between-kidney-transplantation-and-maternal-anti-fetal-rejection/13911/ Program Chairman:Roberto Romero, MD, DMedSciChief, Perinatology Research BranchDivision of Maternal-Fetal Medicine and ObstetricsDivision of Intramural ResearchNICHD/NIH/DHHSEditor-in-Chief for ObstetricsThe American Journal of Obstetrics and Gynecology There exists a long-standing controversy about drawing parallels between transplant and pregnancy immunology. Listen in as Drs. Alexandra Benachi, Julien Zuber, and Lee Shulman discuss why these considerations are so important for you and your colleagues, patients, and their families to understand. Discover how links between kidney transplantation and maternal anti-fetal rejection may impact your practice and spark new pathways in medicine.=

CME credits: 0.50 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/transforming-cervical-cancer-screening-and-management-new-guidelines-new-tests-a-case-based-discussion/14676/ Experts discuss the ACS and ASCCP CCV screening guidelines and review the benefits of primary screening and the latest data driven testing options. Is Pap cytology a thing of the past? Find out more about harmonization of guidelines from leading experts, Drs. Cantrell, Stoler and Huh. You might just transform your clinical practice.

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Masja de Haas, MD, PhD Program Chairman:Roberto Romero, MD, DMedSciChief, Perinatology Research BranchDivision of Maternal-Fetal Medicine and ObstetricsDivision of Intramural ResearchNICHD/NIH/DHHSEditor-in-Chief for ObstetricsThe American Journal of Obstetrics and Gynecology Neonatal alloimmune neutropenia (NAIN or NIN) is a neutrophil blood group antagonism similar to HDFN and FNAIT. Its presentation varies clinically and ranges from asymptomatic to severe manifestations such as sepsis and meningitis. Listen in as Drs. Masja de Haas and Lee Shulman discuss clinical clues that should catch your eye. Discover novel yet simple ways to be vigilant and make the right clinical calls.

CME credits: 0.25 Valid until: 29-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-bone-health-in-postmenopausal-post-fracture-patients/14662/ Life-altering secondary fractures are a harsh reality, but Medicare studies show, and orthopedic surgeons agree, that knowledge has not translated into prevention. Why is there clinical inertia in providing preventative interventions related to secondary fragility fractures? Join Drs. Andrea Singer and Susan Bukata as they provide a cogent medical approach to preventing these fractures and a roadmap for when and how to use available therapies based on their mechanisms of action.

CME credits: 0.25 Valid until: 29-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/alloimmune-neutropenia-of-the-fetus-and-newborn/13910/ Program Chairman:Roberto Romero, MD, DMedSciChief, Perinatology Research BranchDivision of Maternal-Fetal Medicine and ObstetricsDivision of Intramural ResearchNICHD/NIH/DHHSEditor-in-Chief for ObstetricsThe American Journal of Obstetrics and Gynecology Neonatal alloimmune neutropenia (NAIN or NIN) is a neutrophil blood group antagonism similar to HDFN and FNAIT. Its presentation varies clinically and ranges from asymptomatic to severe manifestations such as sepsis and meningitis. Listen in as Drs. Masja de Haas and Lee Shulman discuss clinical clues that should catch your eye. Discover novel yet simple ways to be vigilant and make the right clinical calls.

CME credits: 0.25 Valid until: 14-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/medical-management-of-endometriosis-gnrh-antagonists/14145/ Are you currently considering GnRH antagonists as first-line therapy, or are you waiting for patients to fail other endometriosis treatment approaches first? Drs. Andrea Lukes and Lee Shulman discuss how the advent of effective GnRH antagonists is evolving the care of endometriosis. Are you ready to provide patients with the clinical outcomes they seek while balancing the benefits of medical and surgical approaches?

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: James B. Bussel, MD Program Chairman:Roberto Romero, MD, DMedSciChief, Perinatology Research BranchDivision of Maternal-Fetal Medicine and ObstetricsDivision of Intramural ResearchNICHD/NIH/DHHSEditor-in-Chief for ObstetricsThe American Journal of Obstetrics and Gynecology As the platelet equivalent of hemolytic disease of the fetus and newborn, fetal and neonatal alloimmune thrombocytopenia (FNAIT) is an uncommon yet complex and life-threatening bleeding disorder that results from incompatibility between mother and baby for platelet-specific antigens. Despite relatively normal platelet function, in the setting of severe thrombocytopenia, intracranial hemorrhage is a consequence. Drs. Shulman and Bussel discuss advances in management strategies and concrete steps you can take to lower the risk and stop the progression of this disorder in your patients.

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Linda Bradley, MD Join Drs. Linda Bradley and Lee Shulman as they discuss factors contributing to disparities in care for patients with endometriosis and/or uterine fibroids. They offer practical tips to overcome the disproportionate disease burden that especially impacts women of color. Cut through the noise to clearly hear each patient's voice. Your clinical impact may be profound.

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Kenneth J. Moise Jr., MD Program Chairman: Roberto Romero M.D. D.Med Sci.Chief, Perinatology Research BranchDivision of Maternal-Fetal Medicine and ObstetricsDivision of Intramural ResearchNICHD/NIH/DHHSEditor-in-Chief for ObstetricsThe American Journal of Obstetrics and Gynecology Are you taking the right steps to consistently ensure all of your patients at risk of alloimmune disorders of pregnancy, specifically HDFN, receive a helping hand plus timely and appropriate clinical care? Despite having considerable clinical consequences, this area of medicine is not fully understood by many clinicians. Drs. Shulman and Moise provide expert insight on red blood cell alloimmunization, highlighting essential pathophysiology and current and evolving management strategies. Join us to learn new ways to approach this complicated and rare clinical condition.

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Nanette F. Santoro, MD Tune out the noise and get to the heart of managing menopause and associated vasomotor symptoms. This program provides highlights from the 2022 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting. Join Drs. Nanette Santoro and Lee Shulman as they dive into the latest research, which could alter your current practice patterns and help your patients cool off.

Host: Ayman Al-Hendy, MD Despite its profound impact, endometriosis remains critically undermanaged. This program provides highlights from a live symposium at the annual meeting for obstetrics and gynecology professionals and is based on patient & provider surveys. Join Dr. Ayman Al-Hendy to explore management gaps, the role of GnRH antagonists in addressing deficits, and the latest research, which he presented with Drs. Andrea Lukes and Lee Shulman—you might just alter your current practice patterns.

Host: Jeffery D. Dunn, PharmD, MBA Guest: Gary M. Owens, MD Guest: Anita L. Nelson, MD Are you ready to see what is on the horizon to more effectively navigate vasomotor symptoms (VMS)? Join Drs. Dunn, Owens, and Nelson as they discuss highlights from a symposium held at AMCP 2022 featuring the latest data on the impact of menopause and evolving treatments options. They provide guidance, context, and recommendations for the medical management of VMS beyond estrogen. The nonhormonal treatment options that are currently being studied represent a new horizon for both patients and payers.

Host: Patty Cason, RN, MS, FNP-BC Guest: Joely Pritzker, RN, MS, FNP-C Are you ready to apply the latest counseling techniques to address the contraceptive revolution? Join nurse practitioners Patty Cason and Joely Pritzker as they briefly review the history of contraceptive counseling and then use case vignettes to illustrate how shared decision-making techniques will support the appropriate use of nonhormonal contraceptive options, such as the vaginal pH modulator (VPM). Participating in this activity will ensure that you are ready to effectively counsel patients on their many options so that each patient's reproductive and sexual health goals can be met.